Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia

M. Matsushita, Tatsuhiro Masaoka, Hidekazu Suzuki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system. Purpose: The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2%) than in the placebo group (34.8%). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.

Original languageEnglish
JournalNeurogastroenterology and Motility
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Dyspepsia
Therapeutics
Health Insurance
Acetylcholinesterase
Z 338
Placebos
Muscles

Keywords

  • Acotiamide
  • Functional dyspepsia
  • Postprandial distress syndrome

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Gastroenterology
  • Physiology

Cite this

@article{8df2c5b694da4b39bec79a12265affc6,
title = "Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia",
abstract = "Background: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system. Purpose: The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2{\%}) than in the placebo group (34.8{\%}). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.",
keywords = "Acotiamide, Functional dyspepsia, Postprandial distress syndrome",
author = "M. Matsushita and Tatsuhiro Masaoka and Hidekazu Suzuki",
year = "2016",
doi = "10.1111/nmo.12756",
language = "English",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Emerging treatments in neurogastroenterology

T2 - Acotiamade, a novel treatment option for functional dyspepsia

AU - Matsushita, M.

AU - Masaoka, Tatsuhiro

AU - Suzuki, Hidekazu

PY - 2016

Y1 - 2016

N2 - Background: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system. Purpose: The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2%) than in the placebo group (34.8%). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.

AB - Background: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system. Purpose: The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2%) than in the placebo group (34.8%). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.

KW - Acotiamide

KW - Functional dyspepsia

KW - Postprandial distress syndrome

UR - http://www.scopus.com/inward/record.url?scp=84953209025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953209025&partnerID=8YFLogxK

U2 - 10.1111/nmo.12756

DO - 10.1111/nmo.12756

M3 - Article

C2 - 26730749

AN - SCOPUS:84953209025

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

ER -